Soluble form of CTLA‐4 is a good predictor for tumor recurrence after radiofrequency ablation in hepatocellular carcinoma patients

Teng, Wei; Jeng, Wen–Juei; Chen, Wei‐Ting; Lin, Chen‐Chun; Lin, Chun‐Yen; Lin, Shi‐Ming; Sheen, I‐Shyan

doi:10.1002/cam4.4760

Cited by 8 publications

(7 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Elevated baseline sCTLA4 also correlated with a higher risk of biochemical recurrence and increased progression in prostate cancer patients after treatment with radical prostatectomy, radiotherapy or surveillance [235]. Finally, among patients with hepatocellular carcinoma and chronic hepatitis C, high baseline sCTLA4 correlated with earlier local recurrence and development of intrahepatic metastasis after treatment with radiofrequency ablation [126]. Collectively these studies demonstrate that elevated levels of sCTLA4 prior to therapy associate with poor outcomes in cancer patients treated with a variety of conventional therapies.…”

Section: Sctla4mentioning

confidence: 75%

“…Only a few studies have reported lower levels of sCTLA4 in cancer patients (early breast cancer [66,67], nasopharyngeal carcinoma [65], and clear cell renal cell carcinoma [125]) than in healthy donors. A single study, in patients with hepatocellular carcinoma with chronic hepatitis C infection, found higher concentrations of sCTLA4 to correlate with a later TNM stage and a larger tumor size [126].…”

Section: Sctla4 Expression In Cancer Patient Plasma/serum and Associa...mentioning

confidence: 99%

See 1 more Smart Citation

Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies

Pitts,

Schlom,

Donahue

2024

J Exp Clin Cancer Res

View full text Add to dashboard Cite

Longitudinal sampling of tumor tissue from patients with solid cancers, aside from melanoma and a few other cases, is often unfeasible, and thus may not capture the plasticity of interactions between the tumor and immune system under selective pressure of a given therapy. Peripheral blood analyses provide salient information about the human peripheral immunome while offering technical and practical advantages over traditional tumor biopsies, and should be utilized where possible alongside interrogation of the tumor. Some common blood-based biomarkers used to study the immune response include immune cell subsets, circulating tumor DNA, and protein analytes such as cytokines. With the recent explosion of immune checkpoint inhibitors (ICI) as a modality of treatment in multiple cancer types, soluble immune checkpoints have become a relevant area of investigation for peripheral immune-based biomarkers. However, the exact functions of soluble immune checkpoints and their roles in cancer for the most part remain unclear. This review discusses current literature on the production, function, and expression of nine soluble immune checkpoints – sPD-L1, sPD-1, sCTLA4, sCD80, sTIM3, sLAG3, sB7-H3, sBTLA, and sHVEM – in patients with solid tumors, and explores their role as biomarkers of response to ICI as well as to conventional therapies (chemotherapy, radiotherapy, targeted therapy, and surgery) in cancer patients.

show abstract

Section: Sctla4mentioning

confidence: 75%

Section: Sctla4 Expression In Cancer Patient Plasma/serum and Associa...mentioning

confidence: 99%

Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies

Pitts,

Schlom,

Donahue

2024

J Exp Clin Cancer Res

View full text Add to dashboard Cite

show abstract

“…sCTLA-4, like membrance-bound CTLA-4, can bind to the B7 ligands and interfere with their ligation to CD28, thereby inhibiting T-cell response (Gu et al, 2018). Several studies have supported this by showing that patients with colorectal cancer and hepatocellular carcinoma have high serum sCTLA-4 levels (Omura et al, 2020;Teng et al, 2022).…”

Section: Discussionmentioning

confidence: 99%

Correlation of CTLA‐4 polymorphism and the risk of gastric cancer in a Chinese Bai population

Kong

Zheng

Cheng

et al. 2023

Int J Immunogenetics

View full text Add to dashboard Cite

Cytotoxic T lymphocyte‐associated antigen‐4 (CTLA‐4) is involved in the regulation of immune responses mediated by T cells. This study aimed to explore the correlation between CTLA‐4 gene polymorphisms and the risk of gastric cancer (GC) in the Bai minority population of southwestern China. A total of 422 GC patients and 397 healthy controls (HC) were included in this case–control study. Four single nucleotide polymorphism sites of CTLA‐4 gene (rs231775, rs733618, rs16840252 and rs3087243) were selected and analysed. The results showed a significant difference in the rs733618 loci between GC and HC groups. The frequency of the rs733618 polymorphism ‘TC’ genotype was significantly lower in GC group compared to the HC group [odds ratio (OR), 95% confidence interval (CI): .47 (.35–.63), p < .001]. GC cases with dominant genetic model ‘TC + CC’ had a 47% reduced risk of GC [OR, 95%CI: .53 (.40–.71), p < .001]. Subgroup analyses revealed that the rs733618 ‘TC + CC’ genotype was associated with a lower risk of GC in male patients [OR, 95%CI: .42 (.31–.58), p < .001], those aged ≤60 years old [OR, 95%CI: .27 (.18–.42), p < .001], non‐drinkers [OR, 95%CI: .21 (.13–.33), p < .001], non‐smokers [OR, 95%CI: .38 (.25–.57), p < .001] and individuals without Helicobacter pylori infection [OR, 95%CI: .16 (.10–.26), p < .001]. Further multivariated analyses indicated that individuals with the ‘TC + CC’ rs733618 genotype who were aged ≤60 years old [OR, 95%CI: .42 (.29–.83), p = .032] and had no H. pylori infection [OR, 95%CI: .35 (.28–.76), p = .018] were found to have a protective effect against GC. Additionally, soluble CTLA‐4 were significantly lower in GC patients with ‘TC’ and ‘TC + CC’ genotypes (all p < .05). Our findings suggest that the rs733618 polymorphism of CTLA‐4 gene may play a critical role in the prevention of GC.

show abstract

“…After ablation, assessing the risk of tumor recurrence and monitoring early recurrence are positive preventive strategies that facilitate further management as early as possible in patients. Many biological markers can be used to evaluate tumor recurrence after ablation, including serum markers (e.g., VEGF, 118 sCTLA-4, 119 and CXCL10 73 ) and molecular markers in surgical specimens (e.g., keratin 19 120 ). However, these markers remain to be translated into clinical guidelines.…”

Section: Strategies To Prevent and Treat Hcc Recurrence After Tamentioning

confidence: 99%

Mechanisms and therapeutic strategies to combat the recurrence and progression of hepatocellular carcinoma after thermal ablation

Ye,

Xie,

Liang

et al. 2023

Journal of Interventional Medicine

View full text Add to dashboard Cite

Soluble form of CTLA‐4 is a good predictor for tumor recurrence after radiofrequency ablation in hepatocellular carcinoma patients

Abstract: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 8 publications

References 48 publications

Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies

Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies

Correlation of CTLA‐4 polymorphism and the risk of gastric cancer in a Chinese Bai population

Mechanisms and therapeutic strategies to combat the recurrence and progression of hepatocellular carcinoma after thermal ablation

Contact Info

Product

Resources

About